

# EXHIBIT C1b

February FAC							
Drug Name	Date Drug Considered by EBD	Use	Current Setup	EBD Recommendation (based on input from EBRx and Navitus)	Impacted Members	Cost Details	Commission Decision
mifepristone tab (KORLYM equiv)	March 2024	Hyperglycemia - Idiopathic Cushing's syndrome	Tier 4, PA, QL	Tier 1, PA, QL	0	WAC: \$598/tab	
QVAR REDIMALER	March 2024	Asthma	Not Covered	Tier 2	N/A; adding to formulary	WAC per inhaler: \$213.70-\$286.12	
ALVESCO INHALER	March 2024	Asthma	Not Covered	Tier 2	N/A; adding to formulary	WAC per inhaler: \$274.21	
TOUJEO SOLOSTAR INJ (inner pack NDC only)	March 2024	Diabetes	Tier 2	Not Covered	0	WAC: \$142.86 per pen	
CAPRELSA 100MG TAB	March 2024	Thyroid Cancer	Tier 4, PA	Tier 4, PA, QL = 2 tabs/day, split fill	0	WAC: \$289.21/tab	
CAPRELSA 300MG TAB	March 2024	Thyroid Cancer	Tier 4, PA	Tier 4, PA, QL = 1 tab/day, split fill	0	WAC: \$578.41/tab	
LENVIMA CAP	March 2024	Various Cancers (Thyroid, Liver, Endometrial, Kidney)	Tier 4, PA, QL	Tier 4, PA, QL, split fill	5; only new starts impacted	WAC: \$269.50-\$808.50 per cap pack	
BOSULIF CAP	March 2024	Chronic Myeloid Leukemia	Not Covered	Tier 4, PA	N/A; adding to formulary	Avg: \$15,390/month	
diltiazem ER cap 60, 90, 120mg	March 2024	Hypertension, Arrhythmia	Tier 1	Tier 2 (Grandfather current 23 Members for 90 days and send letter with Tier 1 alternatives)	23	Avg: \$129/month	
VERAPAMIL SR CAP 360mg	March 2024	Hypertension, Arrhythmia	Tier 1	Tier 2 (Grandfather current 23 Members for 90 days and send letter with Tier 1 alternatives)	33	Avg: \$150/month	
CERDELGA CAP	March 2024	Gaucher's Disease	Not Covered	Tier 4, PA	N/A; adding to formulary	Avg: \$29,610/month	
OGSIVEO CAP	March 2024	Desmoid tumors	Not Covered	Tier 4, PA	N/A; adding to formulary	Avg: 23,531/month	
XOLAIR INJ (Does not include self-injectable dosage forms)	March 2024	Asthma, Idiopathic Urticaria, CRwNP	Tier 4, PA	Not Covered on Pharmacy Benefit. Still covered on Medical Benefit.	1	Avg: \$3,779/month	
MAVENCLAD TAB	March 2024	Multiple Sclerosis	Tier 4, PA, QL	Tier 4, PA	0	WAC: \$11,038/month	
REVLIMID CAP	March 2024	Various cancers/blood conditions	Not Covered	Tier 4, Specialist Restriction (hematologist or oncologist), QL	14	Avg: \$14,061/month (generic); \$19,095/month (brand)	

Q1 P&T							
Drug Name	Date Drug Considered by EBD	Use	Current Setup	EBD Recommendation (based on input from EBRx and Navitus)	Impacted Members	Cost Details	Commission Decision
<b>Dry Eye Disease Class Review</b>							
cyclosporine ophth emulsion (RESTASIS equiv)	March 2024	Dry Eye Disease	Tier 2, Specialist Restriction (Ophthalmologist or Optometrist)	Tier 1, Specialist Restriction (Ophthalmologist or Optometrist), QL = 60 vials/30 days	N/A, adding to formulary	Net WAC \$250 per 30 days; place at tier 1 to encourage use of lowest cost generic product	
CEQUA OPHTH SOLN	March 2024	Dry Eye Disease	Tier 2	Tier 2, Specialist Restriction (Ophthalmologist or Optometrist). Grandfather current members.	181 current users will be grandfathered	\$559 per month	
<b>Chronic ITP Class Review</b>							
PROMACTA TAB	March 2024	CITP	Tier 4, PA	Tier 4, PA, QL = 1 tab/day (12.5mg, 25mg), 2 tabs/day (50mg, 75mg)	0 members over QL	WAC \$13,114 per month; Doptelet \$12,348 per month	
PROMACTA POWDER	March 2024	CITP	Tier 4, PA	Tier 4, PA, QL = 1 packet/day	1 member over QL	WAC \$13,114 per month; Doptelet \$12,348 per month	
TAVALISSE TAB	March 2024	CITP	Tier 4, PA, QL	Not Covered. Grandfather current member	1	WAC \$14,620 per month	
<b>Other Products</b>							
Brand HUMIRA products	March 2024	Chronic Inflammatory Diseases	Tier 4, PA, QL	Not Covered Effective 6/1/2024. Providers and impacted members will be notified and educated on the change.	292	- Adalimumab-fkjp: \$477.50/unit - Adalimumab-adaz: \$532.50/unit - Hadlima: \$482.50/unit (For reference: Humira is \$3,462/unit)	
Relyvrio	March 2024	ALS	Tier 4, PA, QL	Not covered. Failed its confirmatory trial and will likely be pulled from the market.	0	AWP \$199,101	